Biofrontera Ag Quick Ratio (BFRA) starting from the fourth quarter 2020 to fourth quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biofrontera Ag  (BFRA)

Biofrontera Ag's Quick Ratio

BFRA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Biofrontera Ag's Cash & cash equivalent grew by 70.69 % in the Q4 2020 sequentially, faster than Current Liabilities, this led to improvement in Biofrontera Ag's Quick Ratio to 2, Quick Ratio remained below Biofrontera Ag average.

Within Major Pharmaceutical Preparations industry 352 other companies have achieved higher Quick Ratio than Biofrontera Ag in fourth quarter 2020. While Quick Ratio total ranking in the fourth quarter 2020 has deteriorated compared to the prior quarter from to 1790.

Explain Quick Ratio?
How much Cash & cash equivalents BFRA´s has?
What are BFRA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BFRA Quick Ratio (Dec 31 2020)
Q4		 (Jun 30 2020)
Q3		 (Dec 31 2019)
Q2		 (Jun 30 2019)
Q1		 (Dec 31 2018)
Q4
Y / Y Current Liabilities Change 16.45 % 2.85 % 49.37 % 135.52 % -
Y / Y Cash & cash equivalent Change -7.11 % -45.58 % -42.7 % 12.66 % -
Quick Ratio MRQ 2 1.32 0.96 1.2 2.5
BFRA's Total Ranking # 1790 # # # #
Seq. Current Liabilities Change 13.22 % -31.14 % -36.58 % 135.52 % 0 %
Seq. Cash & cash equivalent Change 70.69 % -5.03 % -49.14 % 12.66 % 0 %



Quick Ratio fourth quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 353
Healthcare Sector # 591
Overall Market # 1790


Quick Ratio Statistics
High Average Low
6.23 2.48 0.96
(Dec 31 2016)   (Dec 31 2019)




Financial Statements
Biofrontera Ag's Current Liabilities $ 10 Millions Visit BFRA's Balance sheet
Biofrontera Ag's Cash & cash equivalent $ 20 Millions Visit BFRA's Balance sheet
Source of BFRA's Sales Visit BFRA's Sales by Geography


Cumulative Biofrontera Ag's Quick Ratio

BFRA's Quick Ratio for the trailling 12 Months

BFRA Quick Ratio

 (Dec 31 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Dec 31 2018)
12 Months
Y / Y Current Liabilities TTM Growth 51.05 % 95.91 % 127.76 % 150.7 % 134.72 %
Y / Y Cash & cash equivalent TTM Growth -20.68 % 8.13 % 41.66 % 85.62 % 118 %
Quick Ratio TTM 1.31 1.38 1.58 1.93 2.5
Total Ranking TTM # 4883 # # # #
Seq. Current Liabilities TTM Growth 2.8 % 0.49 % 9.22 % 33.88 % 33.33 %
Seq. Cash & cash equivalent TTM Growth -2.19 % -12.32 % -10.35 % 3.17 % 33.33 %

Quick ratio ranking by company, industry and sector >> Back to BFRA Financial Strength Comparisons >> Go to Compare BFRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q4 2020 to $10.13 millions, cumulative Quick Ratio decreased to 1.31 below the Biofrontera Ag average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 466 other companies have achieved higher Quick Ratio than Biofrontera Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from to 4883.

Explain Quick Ratio?
How much Cash & cash equivalents BFRA´s has?
What are BFRA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 467
Healthcare Sector # 894
Within the Market # 4883


trailing twelve months Quick Ratio Statistics
High Average Low
2.5 1.82 0.96
(Dec 31 2018)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Dec 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2020 MRQ Cash & cash equivalentDec 31 2020 MRQ Current Liabilities
Gain Therapeutics inc  5.49 $ 7.493  Millions$ 1.365  Millions
Sarepta Therapeutics Inc   5.49 $ 1,938.571  Millions$ 353.118  Millions
Adc Therapeutics Sa  5.46 $ 439.195  Millions$ 80.490  Millions
Gracell Biotechnologies Inc   5.39 $ 118.475  Millions$ 21.969  Millions
Curevac N v   5.34 $ 1,481.304  Millions$ 277.337  Millions
Corbus Pharmaceuticals Holdings Inc   5.32 $ 169.628  Millions$ 31.898  Millions
Paratek Pharmaceuticals Inc   5.23 $ 125.162  Millions$ 23.953  Millions
Galera Therapeutics Inc   5.21 $ 72.776  Millions$ 13.968  Millions
Cue Biopharma Inc   5.20 $ 84.869  Millions$ 16.316  Millions
Moleculin Biotech Inc   5.20 $ 15.173  Millions$ 2.920  Millions
Addex Therapeutics Ltd  5.16 $ 21.146  Millions$ 4.095  Millions
Opus Genetics Inc   5.15 $ 16.399  Millions$ 3.185  Millions
Phathom Pharmaceuticals Inc   5.09 $ 287.496  Millions$ 56.462  Millions
Protagonist Therapeutics inc   5.09 $ 305.809  Millions$ 60.126  Millions
Arbutus Biopharma Corp  4.99 $ 52.266  Millions$ 10.470  Millions
Morphic Holding inc   4.99 $ 228.264  Millions$ 45.753  Millions
Zymeworks Inc   4.98 $ 426.354  Millions$ 85.666  Millions
Edesa Biotech Inc   4.94 $ 7.214  Millions$ 1.460  Millions
Lunai Bioworks Inc   4.91 $ 3.425  Millions$ 0.698  Millions
Tiziana Life Sciences Ltd  4.85 $ 65.824  Millions$ 13.570  Millions
Merus N v   4.82 $ 225.409  Millions$ 46.746  Millions
Quantum Biopharma Ltd   4.74 $ 17.525  Millions$ 3.700  Millions
Decoy Therapeutics Inc   4.65 $ 11.119  Millions$ 2.390  Millions
Rockwell Medical inc   4.59 $ 58.679  Millions$ 12.793  Millions
Bellerophon Therapeutics inc  4.57 $ 47.660  Millions$ 10.433  Millions
Applied Therapeutics Inc   4.56 $ 96.829  Millions$ 21.235  Millions
Viracta Therapeutics Inc   4.55 $ 47.089  Millions$ 10.338  Millions
Prometheus Biosciences Inc   4.52 $ 54.201  Millions$ 11.980  Millions
Xoma Royalty Corporation  4.49 $ 84.222  Millions$ 18.746  Millions
Maravai Lifesciences Holdings Inc   4.46 $ 236.184  Millions$ 52.937  Millions

Date modified: 2026-09-08T15:09:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.